Last update 01 Nov 2025

LAT-010

Overview

Basic Info

Drug Type
Cytokines
Synonyms
LAT-010
Target
IL-2Rβγ
Action
agonists
Mechanism
IL-2Rβγ agonists(Interleukin-2 Rβγ agonists)
Therapeutic Areas
NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]
Active Indication
Breast CancerColorectal CancerHepatocellular Carcinoma+ [8]
Inactive Indication-
Originator Organization
Latticon Antibody Therapeutics, Inc
Active Organization
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.Latticon Antibody Therapeutics, Inc
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with LAT-010
NCT06277219
/ RecruitingPhase 1/2
A Phase 1/2, Dose-Escalation and Cohort-Expansion Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)
CTR20244740
/ Not yet recruitingPhase 1/2
评估LAT010在中国局部晚期或转移性实体瘤受试者中的安全性、耐受性、药代动力学/药效学、免疫原性和抗肿瘤活性的I/II期临床研究
[Translation] Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, immunogenicity and anti-tumor activity of LAT010 in Chinese subjects with locally advanced or metastatic solid tumors
100 Clinical Results associated with LAT-010
Login to view more data
100 Translational Medicine associated with LAT-010
Login to view more data
100 Patents (Medical) associated with LAT-010
Login to view more data
100 Deals associated with LAT-010
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerPhase 2
United States
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.
13 Dec 2024
Breast CancerPhase 2
China
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.
13 Dec 2024
Colorectal CancerPhase 2
United States
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.
13 Dec 2024
Colorectal CancerPhase 2
China
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.
13 Dec 2024
Hepatocellular CarcinomaPhase 2
United States
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.
13 Dec 2024
Hepatocellular CarcinomaPhase 2
China
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.
13 Dec 2024
MelanomaPhase 2
United States
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.
13 Dec 2024
MelanomaPhase 2
China
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.
13 Dec 2024
Non-Small Cell Lung CancerPhase 2
United States
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.
13 Dec 2024
Non-Small Cell Lung CancerPhase 2
China
Leitekang (Suzhou) Biopharmaceutical Co., Ltd.
13 Dec 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free